How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

746 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Orlistat and sibutramine beyond weight loss

Orlistat and sibutramine beyond weight loss Orlistat and sibutramine beyond weight loss Orlistat and sibutramine beyond weight loss Mannucci E, Dicembrini I, Rotella F, Rotella C M CRD summary This review aimed to assess the effects of orlistat and sibutramine on blood lipids. It concluded that orlistat, but not sibutramine, determined a significant reduction in total cholesterol independent of the weight loss itself. Important information on the methods was missing from the review, so (...) it was impossible to determine whether the conclusions were reliable. Authors' objectives To assess the effects of orlistat and sibutramine on blood lipids independent of weight loss. Searching MEDLINE was searched from inception to the end of May 2005 for relevant English-language articles. Search terms were reported. The reference lists of identified trials and review articles were searched to identify further relevant evidence. Study selection Randomised, double-blind, placebo-controlled trials of six to 12

2008 DARE.

22. Phentermine, Sibutramine and Affective Disorders (PubMed)

Phentermine, Sibutramine and Affective Disorders A safe and effective way to control weight in patients with affective disorders is needed, and phentermine is a possible candidate. We performed a PubMed search of articles pertaining to phentermine, sibutramine, and affective disorders. We compared the studies of phentermine with those of sibutramine. The search yielded a small number of reports. Reports concerning phentermine and affective disorders reported that i) its potency in the central (...) nervous system may be comparatively low, and ii) it may induce depression in some patients. We were unable to find more studies on the subject; thus, it is unclear presently whether phentermine use is safe in affective disorder patients. Reports regarding the association of sibutramine and affective disorders were slightly more abundant. A recent study that suggested that sibutramine may have deleterious effects in patients with a psychiatric history may provide a clue for future phentermine research

Full Text available with Trip Pro

2013 Clinical Psychopharmacology and Neuroscience

23. Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects. (PubMed)

Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects. In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans. Sibutramine showed enantioselective plasma profiles with consistently higher concentrations of R-enantiomers (...) . Clopidogrel and clarithromycin significantly increased the sibutramine plasma concentration, but their effects differed between enantiomers; a 2.2-fold versus 4.1-fold increase in the AUC in S-enantiomer and 1.8-fold versus 2.0-fold for the R-enantiomer, respectively. The AUCs of S- and R-desmethyl metabolites changed significantly during the clopidogrel phase (P < .001 and P < .001, respectively) but not during the clarithromycin phase (P = .099 and P = .090, respectively). Exposure to sibutramine

2013 Journal of clinical pharmacology Controlled trial quality: uncertain

24. The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function.

The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function. Obesity is associated with impaired microvascular endothelial function. We aimed to determine the effects of orlistat and sibutramine treatment on microvascular endothelial function, anthropometric and lipid profile, blood pressure (BP), and heart rate (HR).76 subjects were recruited and randomized to receive orlistat 120 mg three times daily or sibutramine 10 mg daily for 9 months (...) . AChmax, ACh % change and ACh peak were increased in orlistat-treated group but no difference was observed for sibutramine-treated group. BP and total cholesterol (TC) were reduced for orlistat-treated group. HR was reduced for orlistat-treated group but was increased in sibutramine-treated group.9 months treatment with orlistat significantly improved microvascular endothelial function. This was associated with reductions in weight, BMI, BP, HR, TC and low density lipoprotein cholesterol. No effect

2013 Clinical hemorheology and microcirculation

25. Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. (PubMed)

Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. The effects of linagliptin on fat content in diet-induced obese rats were compared with those of the appetite suppressant sibutramine. Female Wistar rats fed a high-fat diet (HFD) for 3 months received vehicle, linagliptin (10 mg/kg) or sibutramine (5 mg/kg) treatment orally, once daily for 6 additional weeks, while (...) continuing the HFD. Magnetic resonance spectroscopy analysis of fat content was performed at baseline and at the end of the 6-week treatment period. Linagliptin treatment profoundly reduced hepatic fat compared with vehicle, with an effect comparable to that of sibutramine. The vehicle-corrected mean change (95% CI) from baseline in hepatic fat and intramyocellular lipid was -59.0% (-104.3%, -13.6%; p = 0.015) and -62.1% (-131.6%, 7.4%; p = 0.073), respectively, for linagliptin compared with -54.3

2012 obesity & metabolism

26. Sibutramine

Sibutramine Sibutramine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Sibutramine Sibutramine Aka: Sibutramine , Meridia From (...) Related Chapters II. Background Sibutramine taken off the market October 2010 in United States due to risk of serious cardiovascular events Listed for historical purposes only III. Contraindications Severe Hepatic insufficiency Advanced cardiovascular disease Arrhythmias Narrow-Angle history IV. Dosing Continuous: Sibutramine 15 mg qd Intermittent (similar weight loss, less side effects) Weeks 1-12: Sibutramine 15 mg qd Weeks 19-30: Sibutamine 15 mg qd Weeks 37-48: Sibutramine 15 mg qd No medication

2015 FP Notebook

27. A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity. (PubMed)

A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity. In this study, we aimed to explore whether a common single nucleotide polymorphism (SNP), rs266729 (-11,377C > G), in the adiponectin C1Q and collagen domain containing (ADIPOQ) gene could influence weight reduction and fat change under sibutramine therapy in an obese population. There were 131 obese Taiwanese patients, including 44 in the placebo group and 87 in the sibutramine (...) (10 mg daily) group. We assessed the measures of weight loss and body fat reduction at the end of the 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and baseline percent body fat as covariates. By comparing the placebo and sibutramine groups with ANCOVA, our data revealed a strong effect of sibutramine on percent body fat loss (1.9 ± 0.3 vs 4.6 ± 0.5%; P < 0.001) and on weight reduction (2.8 ± 2.0 vs 7.9 ± 1.6 kg; P < 0.001) for subjects

Full Text available with Trip Pro

2012 Clinical pharmacology : advances and applications Controlled trial quality: uncertain

28. Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. (PubMed)

Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Elevated levels of serum uric acid are associated with an increased risk of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle plus sibutramine) in an overweight and obese cardiovascular high risk population was studied.Data from a four week single-blind lead-in period (...) of the Sibutramine Cardiovascular OUTcomes (SCOUT) study were analyzed. 2584 patients (24%) had diabetes mellitus (DM) only, 1748 (16%) had cardiovascular disease (CVD) only and 6397 (60%) had both DM + CVD. Uric acid concentrations (mean +/- standard deviation) at screening were significantly higher among patients with CVD compared to patients without CVD (p < 0.0001): 369 +/- 86 mumol/L, 374 +/- 98 mumol/L and 342 +/- 87 mumol/L in CVD only, CVD+DM and DM only groups, respectively. During treatment uric acid

Full Text available with Trip Pro

2012 Nutrition & metabolism Controlled trial quality: uncertain

29. Sibutramine promotes amygdala activity under fasting conditions in obese women. (PubMed)

Sibutramine promotes amygdala activity under fasting conditions in obese women. Sibutramine, a centrally-acting selective monoamine reuptake inhibitor, has been used as an appetite suppressant drug in obesity.To gain insight into the central nervous actions of sibutramine, brain responses to pictures of food items after sibutramine vs placebo application were assessed by functional magnetic resonance imaging (fMRI) in obese women.In a randomized double-blind crossover design, 10 healthy obese (...) women (BMI 31.8-39.9 kg/m(2)) received 15 mg/d of sibutramine vs placebo for 14 d. Obese participants, and a group of 10 age-matched normal weight controls, viewed pictures of food items and control objects in hungry and satiated states while lying in the MR scanner. The paradigm followed a block design. In obese participants, fMRI measurements were conducted prior and after two weeks of daily sibutramine or placebo administration, whereas control participants were scanned only at one point

2012 Psychopharmacology Controlled trial quality: uncertain

30. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. (PubMed)

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality. The relationship between 12-month weight loss and subsequent cardiovascular outcomes is explored.Overweight/obese subjects (N = 10 744), ≥55 years with cardiovascular disease and/or type 2 (...) diabetes mellitus, received sibutramine plus weight management during a 6-week Lead-in Period before randomization to continue sibutramine (N = 4906) or to receive placebo (N = 4898). The primary endpoint was the time from randomization to first occurrence of a primary outcome event (non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest or cardiovascular death).For the total population, mean weight change during Lead-in Period (sibutramine) was -2.54 kg. Post-randomization

2012 obesity & metabolism Controlled trial quality: uncertain

31. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. (PubMed)

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. The prevalence of obesity, a serious public health problem, is increasing among teenagers and thus also increases cardiovascular morbidity and mortality in adulthood.To provide a systematic review of the best evidence about the effect of sibutramine and orlistat in weight loss, quality of life and its adverse effects in adolescents diagnosed (...) with obesity.We searched electronic databases and bibliographies of selected articles were inspected for any further reference. We included only randomized controlled trials that met a set of predefined criteria. The studies were reviewed by a narrative synthesis.We included 6 randomized controlled trials of sibutramine and 3 of orlistat. The majority reached a moderate to high methodological quality. Sibutramine and orlistat showed a reduction in body mass index (BMI) that was significantly higher compared

2011 Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral

32. Inverse Agonism at α2A Adrenoceptors Augments the Hypophagic Effect of Sibutramine in Rats. (PubMed)

Inverse Agonism at α2A Adrenoceptors Augments the Hypophagic Effect of Sibutramine in Rats. Because the use of monoamine reuptake inhibitors as weight-reducing agents is limited by adverse effects, novel antiobesity drugs are needed. We studied acute effects of the noradrenaline (NA) and serotonin (5-HT) reuptake inhibitor sibutramine (SIB), alone and after pretreatment with α1- and α2-adrenoceptor (AR), and 5-HT1/2/7, 5-HT1B and 5-HT2C receptor antagonists in order to determine which ARs and 5

Full Text available with Trip Pro

2011 Obesity

33. Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects

Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects (sibu) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01421706 Recruitment Status : Completed First Posted : August 23, 2011 Last Update Posted

2011 Clinical Trials

34. Sibutramine on Cardiovascular Outcome (PubMed)

Sibutramine on Cardiovascular Outcome 21525441 2011 07 01 2018 11 13 1935-5548 34 Suppl 2 2011 May Diabetes care Diabetes Care Sibutramine on cardiovascular outcome. S114-9 10.2337/dc11-s205 Scheen André J AJ Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Department of Medicine, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium. andre.scheen@chu.ulg.ac.be eng Journal Article Review United States Diabetes Care 7805975 0149 (...) -5992 0 Appetite Depressants 0 Cyclobutanes WV5EC51866 sibutramine IM Appetite Depressants adverse effects therapeutic use Cardiovascular Diseases chemically induced Cardiovascular System drug effects Cyclobutanes adverse effects therapeutic use Humans 2011 4 29 6 0 2011 5 6 6 0 2011 7 2 6 0 ppublish 21525441 34/Supplement_2/S114 10.2337/dc11-s205 PMC3632147 Obes Rev. 2010 Nov;11(11):777-91 20025693 N Engl J Med. 2010 Sep 2;363(10):905-17 20818901 CMAJ. 2002 May 14;166(10):1307-8 12041851 Obes Rev

Full Text available with Trip Pro

2011 Diabetes Care

35. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. (PubMed)

Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. The efficacy of sibutramine has been demonstrated in randomized trials in obese/overweight patients including those with type 2 diabetes mellitus (T2DM). Our objective was to evaluate the effects of 1-year treatment with sibutramine compared to placebo on body weight, glycaemic control, lipid profile, and inflammatory parameters in type 2 diabetic patients.Two hundred and forty-six (...) patients with uncontrolled T2DM [glycated haemoglobin (HbA(1c) ) > 8·0%] in therapy with different oral hypoglycaemic agents or insulin were randomized to take 10 mg of sibutramine or placebo for 12 months. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA(1c) , fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total

2011 Journal of clinical pharmacy and therapeutics Controlled trial quality: uncertain

36. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. (PubMed)

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management (...) with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal

Full Text available with Trip Pro

2010 NEJM Controlled trial quality: predicted high

37. Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. (PubMed)

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. Sibutramine and metformin are drugs commonly used to obtain weight loss. We aimed to compare the effects of sibutramine alone with that of sibutramine plus metformin combination on weight loss, insulin sensitivity, leptin and C reactive protein in obese women. Seventy obese women were included. After a diet period of month (baseline), each individual was randomly assigned to receive 15 mg sibutramine (...) (sibutramine group; n = 36) or 15 mg sibutramine plus 1,700 mg metformin per day (sibutramine plus metformin group; n = 34) during the next 12 months. Body weight, insulin resistance by the homeostasis model assessment model (HOMA-IR), leptin and C reactive protein were measured at baseline, after 3 months and after 12 months. Mean weight losses in sibutramine and sibutramine plus metformin groups were 5.3 +/- 4.0% (P < 0.001) and 6.8 +/- 3.9% (P < 0.001) after 3 months, and 10.5 +/- 4.4% (P < 0.001

2010 Clinical and experimental medicine Controlled trial quality: uncertain

38. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. (PubMed)

Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. To assess treatment responses to sibutramine and weight management in diabetic patients during the lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.SCOUT is an ongoing, prospective, randomized, double-blind, placebo-controlled outcome trial (...) in cardiovascular high-risk overweight/obese patients. A total of 10 742 patients received single-blind sibutramine and individualized weight management during the 6-week lead-in period; 84% had a history of type 2 diabetes mellitus and additional co-morbidities. Post-hoc analyses assessed anthropomorphic and vital sign responses between patients with and without diabetes.Concomitant antidiabetic medication use was reported by 86% of the diabetic patients (approximately 30% required insulin-alone

2010 obesity & metabolism Controlled trial quality: uncertain

39. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. (PubMed)

Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. To evaluate the effects of one year of treatment with sibutramine plus L-carnitine compared to sibutramine on body weight, glycemic control, and insulin resistance state in type 2 diabetic patients.Two hundred and fifty-four patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA(1c)) >8.0%] in therapy with different oral hypoglycemic agents or insulin were enrolled (...) in this study and randomised to take sibutramine 10 mg plus L-carnitine 2 g or sibutramine 10 mg in monotherapy. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), glycated hemoglobin (HbA(1c)), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein

2010 Internal medicine (Tokyo, Japan) Controlled trial quality: uncertain

40. Sibutramine should be excluded from use in obese patients with preexisting cardiovascular disease (PubMed)

Sibutramine should be excluded from use in obese patients with preexisting cardiovascular disease 21977163 2011 11 10 2011 10 06 2069-6116 5 3 2010 Jul Maedica Maedica (Buchar) Sibutramine should be excluded from use in obese patients with preexisting cardiovascular disease. 229-30 Constantinescu Maria Cristina MC Cardiology Department, Emergency University Hospital, Bucharest, Romania. eng Journal Article Romania Maedica (Buchar) 101526930 1841-9038 2011 10 7 6 0 2010 7 1 0 0 2010 7 1 0 1

Full Text available with Trip Pro

2010 Mædica

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>